Healthcare / Medical DevicesASX
$0.04
-0.00 (-2.50%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-4.8M · quality 77.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$45M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-443.8%
↓Gross Margin
100.0%
↑Debt/Equity
0.30
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-3.0%
FCF CAGR
—
FCF margin
-1246.7%
FCF / Net income
0.89x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $293380.0 · net income $-4.1M · FCF $-3.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $293380.00 | $293380.00 | $364328.00 | $591364.16 | $321791.92 |
| Net Income | $-4.1M | $-4.1M | $-5.5M | $-6.6M | $-7.2M |
| EBITDA | $-4.0M | $-4.0M | $-5.1M | $-5.8M | $-4.1M |
| EPS | -0.00 | -0.00 | -0.01 | -0.02 | -0.03 |
| Gross Margin | 100.0% | 100.0% | 60.0% | 60.0% | 64.2% |
| Operating Margin | -1228.1% | -1228.1% | -1528.4% | -1100.1% | -1453.0% |
| Net Margin | -1408.3% | -1408.3% | -1507.0% | -1117.6% | -2229.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.30 | 0.30 | 0.29 | 0.45 | 0.06 |
| Current Ratio | 4.49 | 4.49 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.7M | $-3.7M | $-4.8M | $-5.6M | $-4.8M |
| Returns | |||||
| ROE | -443.8% | -443.8% | -198.1% | -964.8% | -170.6% |
| Valuation | |||||
| P/B | 44.83 | 44.83 | 3.65 | 8.75 | 6.62 |
| Growth & Yield | |||||
| Revenue Growth | -19.5% | -19.5% | -38.4% | 83.8% | — |
| EPS Growth | 62.1% | 62.1% | 57.8% | 26.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+225.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.01 → -0.00
Residual
+225.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.